Stocktoria
Metagenomi Therapeutics, Inc. MGX
Metagenomi Therapeutics, Inc. (MGX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $25.2M at a -348.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.645 |
| Retained earnings / assets | -1.406 |
| EBIT / assets | -0.434 |
| Equity / liabilities | 2.537 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MGX | Metagenomi Therapeutics, Inc. | 1/9 | -0.61 | — | -51.8% |
| ALEC | Alector, Inc. | 1/9 | -9.85 | — | -79.1% |
| SCLX | Scilex Holding Co | 2/9 | — | — | -46.5% |
| LENZ | LENZ Therapeutics, Inc. | 2/9 | 15.45 | — | — |
| PTHS | Pelthos Therapeutics Inc. | 4/9 | -1.47 | — | — |
| DTIL | PRECISION BIOSCIENCES INC | 1/9 | -7.2 | — | -50.1% |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
FAQ
Is MGX financially healthy?
Metagenomi Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MGX pay a dividend?
No, Metagenomi Therapeutics, Inc. does not currently pay a dividend.
How profitable is MGX?
In FY2025, Metagenomi Therapeutics, Inc. had a net margin of -348.5% and a return on equity of -55.4%.
What is the analyst price target for MGX?
The average Wall-Street price target for Metagenomi Therapeutics, Inc. is $8.00, about 555.7% above the recent price, from 2 analysts.
Is MGX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Metagenomi Therapeutics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.